Across TCGA pan-cancer cohorts, GLRXP3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GLRXP3 data layer compared with 16 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher GLRXP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLRXP3 expression acts as an unfavorable survival marker.
ESCA are the cancer types where GLRXP3 Mutation most reproducibly stratifies survival.